Dennis Cho Sells 3,104 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 3,104 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $134,123.84. Following the completion of the transaction, the insider now directly owns 75,289 shares of the company’s stock, valued at approximately $3,253,237.69. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Dennis Cho also recently made the following trade(s):

• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total transaction of $10,983.96.
• On Monday, August 5th, Dennis Cho sold 709 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total value of $28,310.37.

Twist Bioscience Price Performance

Shares of TWST opened at $43.34 on Friday. The company’s 50-day moving average is $44.94 and its 200-day moving average is $43.69. The firm has a market capitalization of $2.52 billion, a PE ratio of -12.90 and a beta of 1.77. Twist Bioscience Co. has a fifty-two week low of $14.42 and a fifty-two week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same period in the prior year, the company earned ($1.01) earnings per share. The firm’s revenue was up 27.7% compared to the same quarter last year. Analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

Several institutional investors have recently added to or reduced their stakes in the company. Baillie Gifford & Co. lifted its holdings in shares of Twist Bioscience by 12.1% during the first quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock worth $42,116,000 after buying an additional 132,770 shares in the last quarter. Point72 Asset Management L.P. increased its position in Twist Bioscience by 1,021.8% during the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after acquiring an additional 613,057 shares during the period. Fred Alger Management LLC increased its position in Twist Bioscience by 720.7% during the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after acquiring an additional 575,080 shares during the period. Driehaus Capital Management LLC raised its stake in Twist Bioscience by 63.0% in the 2nd quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock worth $19,152,000 after purchasing an additional 150,260 shares in the last quarter. Finally, Ensign Peak Advisors Inc boosted its holdings in Twist Bioscience by 74.6% in the 2nd quarter. Ensign Peak Advisors Inc now owns 331,373 shares of the company’s stock valued at $16,330,000 after purchasing an additional 141,557 shares during the period.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of analyst reports. Evercore ISI raised their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird boosted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. TD Cowen increased their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Finally, Barclays dropped their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.63.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.